KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Intangibles (2019 - 2021)

Royalty Pharma's Intangibles history spans 2 years, with the latest figure at $5.7 million for Q4 2021.

  • For Q4 2021, Intangibles changed N/A year-over-year to $5.7 million; the TTM value through Dec 2021 reached $5.7 million, changed N/A, while the annual FY2021 figure was $5.7 million, N/A changed from the prior year.
  • Intangibles for Q4 2021 was $5.7 million at Royalty Pharma, down from $51.7 million in the prior quarter.
  • Across five years, Intangibles topped out at $51.7 million in Q4 2019 and bottomed at $5.7 million in Q4 2021.